CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Biotech
Original article

Orsini to Serve as Specialty Pharmacy Partner for Priovant's LISRAYA™ (brepocitinib)

PartnershipLISRAYAPositive
AI Analysis

Summary

Orsini announced a specialty pharmacy partnership for Priovant's LISRAYA (brepocitinib), the first FDA-approved targeted therapy for dermatomyositis.

Importance:3/10
Sentiment:
0.30
specialty pharmacyFDA-approvedrare diseasepartnershipdermatomyositis
Related Companies

Read the original article

Published by PR Newswire Biotech on August 28, 2026 3:41 PM

Read Original